

# Question 1

- Discuss the benefits of using salmeterol for the treatment of asthma in patients not adequately controlled on other asthma-controller medications (eg, low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies, in each of the following age groups:
  - In adults [ $\geq 18$  years of age]
  - In adolescents [12-17 years of age]
  - In children [4-11 years of age]

## Question 2

- Discuss the benefits of using formoterol for the treatment of asthma in patients not adequately controlled on other asthma-controller medications (eg, low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies, in each of the following age groups:
  - In adults [ $\geq 18$  years of age]
  - In adolescents [12-17 years of age]
  - In children [5-11 years of age]

## Question 3

- Discuss the risks of using salmeterol for the treatment of asthma in patients not adequately controlled on other asthma-controller medications (eg, low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies, in each of the following age groups:
  - In adults [ $\geq 18$  years of age]
  - In adolescents [12-17 years of age]
  - In children [4-11 years of age]

## Question 4

- Discuss the risks of using formoterol for the treatment of asthma in patients not adequately controlled on other asthma-controller medications (eg, low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies, in each of the following age groups:
  - In adults [ $\geq 18$  years of age]
  - In adolescents [12-17 years of age]
  - In children [5-11 years of age] (Note that Symbicort is not indicated in this age group)

## Question 5

- Do the benefits of Serevent (salmeterol xinafoate) outweigh its risks for the maintenance treatment of asthma in patients not adequately controlled on other asthma-controller medications (eg, low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies, in the following age groups:
  - In adults [ $\geq 18$  years of age] (Voting question)
  - In adolescents [12-17 years of age] (Voting question)
  - In children [4-11 years of age] (Voting question)

## Question 6

- Do the benefits of Foradil (formoterol fumarate) outweigh its risks for the maintenance treatment of asthma in patients not adequately controlled on other asthma-controller medications (eg, low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies, in the following age groups:
  - In adults [ $\geq 18$  years of age] (Voting question)
  - In adolescents [12-17 years of age] (Voting question)
  - In children [5-11 years of age] (Voting question)

## Question 7

- Do the benefits of Advair (fluticasone propionate; salmeterol xinafoate) outweigh its risks for the maintenance treatment of asthma in patients not adequately controlled on other asthma-controller medications (eg, low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies, in the following age groups:
  - In adults [ $\geq 18$  years of age] (Voting question)
  - In adolescents [12-17 years of age] (Voting question)
  - In children [4-11 years of age] (Voting question)

## Question 8

- Do the benefits of Symbicort (budesonide and formoterol fumarate dihydrate) outweigh its risks for the maintenance treatment of asthma in patients not adequately controlled on other asthma-controller medications (eg, low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies, in the following age groups:
  - In adults [ $\geq 18$  years of age] (Voting question)
  - In adolescents [12-17 years of age] (Voting question)



## Question 9

- Based on your discussion and votes above, are there further labeling changes or risk mitigation strategies for individual LABA products, or the class as a whole, that would be advisable?

## Question 10

- What further studies, if any, would clarify important unanswered questions of safety and efficacy for individual LABA products or the class as a whole?